Portal de Periódicos da CAPES

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

2009; Massachusetts Medical Society; Volume: 361; Issue: 8 Linguagem: Inglês

10.1056/nejmoa0809003

1533-4406

Matthew Smith, Blair Egerdie, Narciso Hernández Toriz, Robert Feldman, Teuvo L.J. Tammela, Fred Saad, Jiří Heráček, Maciej Szwedowski, Chunlei Ke, Amy Kupic, Benjamin Z. Leder, Carsten Goessl,

Bone health and osteoporosis research

Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-κB ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.